Charles Schwab
TEVA icon

Charles Schwab’s Teva Pharmaceuticals TEVA Stock Holding History

Charles Schwab’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.5M Buy
2,140,582
+52,903
+3% +$1.76M 0.01% 984
2026
Q1 		$62.9M Sell
2,087,679
-42,984
-2% -$1.38M 0.01% 1002
2025
Q4 		$66.5M Buy
2,130,663
+200,222
+10% +$4.93M 0.01% 964
2025
Q3 		$39M Buy
1,930,441
+315,712
+20% +$5.55M 0.01% 1312
2025
Q2 		$27.1M Buy
1,614,729
+289,793
+22% +$4.68M ﹤0.01% 1503
2025
Q1 		$20.4M Buy
1,324,936
+296,012
+29% +$5.29M ﹤0.01% 1633
2024
Q4 		$22.7M Buy
1,028,924
+129,749
+14% +$2.36M ﹤0.01% 1631
2024
Q3 		$16.2M Buy
899,175
+177,836
+25% +$3.11M ﹤0.01% 1811
2024
Q2 		$11.7M Buy
721,339
+26,399
+4% +$407K ﹤0.01% 1965
2024
Q1 		$9.81M Buy
694,940
+28,294
+4% +$357K ﹤0.01% 1993
2023
Q4 		$6.96M Sell
666,646
-19,766
-3% -$185K ﹤0.01% 2171
2023
Q3 		$7M Buy
686,412
+52,436
+8% +$488K ﹤0.01% 2103
2023
Q2 		$4.77M Buy
633,976
+21,741
+4% +$176K ﹤0.01% 2250
2023
Q1 		$5.42M Sell
612,235
-7,605
-1% -$75.2K ﹤0.01% 2165
2022
Q4 		$5.65M Sell
619,840
-7,580
-1% -$66.1K ﹤0.01% 2154
2022
Q3 		$5.06M Buy
627,420
+23,763
+4% +$210K ﹤0.01% 2211
2022
Q2 		$4.54M Buy
603,657
+17,686
+3% +$154K ﹤0.01% 2228
2022
Q1 		$5.5M Buy
585,971
+20,600
+4% +$172K ﹤0.01% 2226
2021
Q4 		$4.53M Buy
565,371
+17,473
+3% +$158K ﹤0.01% 2394
2021
Q3 		$5.34M Buy
547,898
+17,101
+3% +$160K ﹤0.01% 2343
2021
Q2 		$5.25M Hold
530,797
– – ﹤0.01% 2326
2021
Q1 		$6.13M Buy
530,797
+27,383
+5% +$314K ﹤0.01% 2194
2020
Q4 		$4.86M Buy
503,414
+13,232
+3% +$127K ﹤0.01% 2236
2020
Q3 		$4.42M Buy
490,182
+12,358
+3% +$131K ﹤0.01% 2123
2020
Q2 		$5.89M Buy
477,824
+13,378
+3% +$151K ﹤0.01% 1947
2020
Q1 		$4.17M Buy
464,446
+42,741
+10% +$438K ﹤0.01% 1922
2019
Q4 		$4.13M Buy
421,705
+10,735
+3% +$95.8K ﹤0.01% 2124
2019
Q3 		$2.83M Buy
410,970
+16,165
+4% +$124K ﹤0.01% 2254
2019
Q2 		$3.65M Buy
394,805
+53,963
+16% +$651K ﹤0.01% 2125
2019
Q1 		$5.34M Buy
340,842
+13,135
+4% +$232K ﹤0.01% 1955
2018
Q4 		$5.05M Buy
327,707
+21,355
+7% +$438K ﹤0.01% 1896
2018
Q3 		$6.6M Buy
306,352
+9,118
+3% +$212K ﹤0.01% 1895
2018
Q2 		$7.23M Buy
297,234
+20,714
+7% +$422K 0.01% 1806
2018
Q1 		$4.73M Buy
276,520
+11,601
+4% +$227K ﹤0.01% 1974
2017
Q4 		$5.02M Buy
264,919
+17,359
+7% +$261K ﹤0.01% 1918
2017
Q3 		$4.36M Buy
247,560
+5,989
+2% +$135K ﹤0.01% 1945
2017
Q2 		$8.03M Buy
241,571
+17,116
+8% +$530K 0.01% 1504
2017
Q1 		$7.2M Hold
224,455
– – 0.01% 1543
2016
Q4 		$8.14M Buy
+224,455
New +$8.96M 0.01% 1412

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Charles Schwab's TEVA Position: Q2 2026 in Review

Charles Schwab increased its Teva Pharmaceuticals (TEVA) stake by 2.5% in Q2 2026, buying an estimated $1.76M and bringing the position to 2,140,582 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #984.

Charles Schwab first reported a position in TEVA in Q4 2016 and has held it in 39 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Charles Schwab held 2,140,582 shares of Teva Pharmaceuticals worth $72.5M as of Q2 2026.
  • Charles Schwab bought 52,903 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
  • Teva Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #984 holding.
  • Charles Schwab first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.